Skip to main content
Premium Trial:

Request an Annual Quote

DiaCarta Molecular Test for SARS-CoV-2, Variants Obtains CE Mark

NEW YORK ─ Liquid biopsy test developer DiaCarta said Thursday it has obtained the CE mark for its QuantiVirus SARS-CoV-2 Variant Detection Test, enabling its use in the European Union and other regions that accept the designation.

This test screens for the SARS-CoV-2 virus and identifies and differentiates between mutating COVID-19 variants of concern, including the Alpha, Beta, Gamma, Delta, Delta Plus, Epsilon, and Kappa variants, and can run on available qPCR cyclers, bypassing the need to conduct NGS testing, DiaCarta said.

The test can also "provide an expeditious, inexpensive solution for variant surveillance," Aiguo Zhang, founder and CEO of DiaCarta, said in a statement.

It leverages molecular clamping technology in which synthetic xenonucleic acid oligomers hybridize with target DNA sequences and become molecular clamps during qPCR. The XNA are tightly bound to wild-type sequences so that only the mutant sequences are accurately amplified, DiaCarta said.

The Pleasanton, California-based company is pursuing a US Food and Drug Administration Emergency Use Authorization for the test, it added.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.